Meeting
2014 Gastrointestinal Cancers Symposium
A phase II study of cetuximab (cet) and mFOLFOX6 in metastatic colorectal cancer (mCRC) (JACCRO CC-05).
Authors
Tatsuro Yamaguchi
Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
Tatsuro Yamaguchi , Akihito Tsuji , Yu Sunakawa , Masato Nakamura , Mitsugu Kochi , Tadamichi Denda , Ken Shimada , Satoshi Tani , Akinori Takagane , Masahito Kotaka , Hidekazu Kuramochi , Junichi Koike , Kaoru Furushima , Yutaka Yonemura , Yuji Negoro , Yasutaka Takinishi , Masahiro Takeuchi , Wataru Ichikawa , Masashi Fujii , Toshifusa Nakajima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000004197
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 611)
DOI
10.1200/jco.2014.32.3_suppl.611
Abstract #
611
Poster Bd #
E2
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.
First Author: Jianming Xu
Poster
2022 ASCO Annual Meeting
First-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress.
First Author: Jong-Mu Sun
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015.
First Author: Deirdre Jill Cohen